Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 3/20 | 0.58 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.45 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.45 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.45 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PIK3C2B | O00750 | 4/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | KHK | P50053 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440733 | 0.92 | PRKDC (0.65) | PRKDCP2RX4MAPTPIK3C2BPIK3CD | |
| SCHEMBL5444170 | 0.90 | PRKDC (0.55) | PRKDCPLOD2PLOD3PLOD1P2RX4 | |
| SCHEMBL5440678 | 0.81 | PRKDC (0.61) | PRKDCMAPTPIK3C2BPIK3CDPIK3CA | |
| SCHEMBL14802160 | 0.78 | PRKDC (0.68) | PRKDCMAPTPIK3C2BPIK3CDPIK3CA | |
| SCHEMBL5444182 | 0.73 | PRKDC (1.00) | PRKDCP2RX4MAPTPIK3C2BPIK3CD | |
| SCHEMBL5454434 | 0.71 | MGAM (0.63) | PRKDC | |
| SCHEMBL5440644 | 0.69 | PRKDC (0.55) | PRKDCMAPTPIK3C2BPIK3CDPIK3CA | |
| SCHEMBL5446315 | 0.67 | MAOA (0.64) | PRKDCMAPT | |
| SCHEMBL5442834 | 0.67 | PRKDC (0.48) | PRKDCPLOD2PLOD3PLOD1MAPT | |
| SCHEMBL29754967 | 0.66 | CYP2C9 (0.45) | P2RX4MAPTCYP2C9HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | DCK, DTYMK, XPA | PRKDC 12/4885PLOD2 4641/4885PLOD3 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.